Tesamorelin + Ipamorelin

Tesamorelin + Ipamorelin Blend | Dual-Pathway GHRH/GHRP

A precision-engineered blend designed to study the maximal pulsatile release of growth hormone through dual receptor agonism.

This formulation combines Tesamorelin (a GHRH analogue) and Ipamorelin (a selective GHRP). In endocrine research, this combination is utilized to study the synergistic effect of simultaneous pituitary stimulation. While Tesamorelin provides the signal for GH production, Ipamorelin amplifies the pulse and suppresses somatostatin, resulting in a significantly more potent GH release than either peptide alone.

Synergistic Research Focus

• Amplified GH Pulsatility: Studying the peak concentration of growth hormone via dual signaling.
• Metabolic Efficiency: Investigating the combined impact on visceral fat loss and lean mass preservation.
• Selectivity: Researching high GH output without the elevation of cortisol or prolactin.

Scientific Reference Library

• 🧪 Research: Synergistic stimulation of GH by GHRH and GHRP analogues
• 🧪 Research: Dual-pathway approaches to somatotropic activation
• 🧪 Research: Impact of combined secretagogues on adipose tissue distribution